At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of Long-Acting Injectable Medications for Schizophrenia
In Brief
A Phase 4 clinical trial evaluating haloperidol decanoate and paliperidone palmitate for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 311 participants across 22 sites.
Detailed Summary
The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).
Study Details
Timeline
Interventions
haloperidol decanoate injections, 25-200 mg once a month
Paliperidone palmitate injections, 39 mg - 234 mg once a month